BeOne Medicines (STU:49B) Additional Paid-In Capital : €11,329 Mil(As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is BeOne Medicines Additional Paid-In Capital?

BeOne Medicines's quarterly additional paid-in capital increased from Sep. 2024 (€10,789 Mil) to Dec. 2024 (€11,544 Mil) but then stayed the same from Dec. 2024 (€11,544 Mil) to Mar. 2025 (€11,329 Mil).

BeOne Medicines's annual additional paid-in capital declined from Dec. 2022 (€10,895 Mil) to Dec. 2023 (€10,636 Mil) but then increased from Dec. 2023 (€10,636 Mil) to Dec. 2024 (€11,544 Mil).

BeOne Medicines Additional Paid-In Capital Historical Data

The historical data trend for BeOne Medicines's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeOne Medicines Additional Paid-In Capital Chart

BeOne Medicines Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

6,095.07

9,904.04

10,894.68

10,636.00

11,543.95

BeOne Medicines Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															10,768.66	10,999.54	10,788.95	11,543.95	11,328.72

BeOne Medicines Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

BeOne Medicines Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of BeOne Medicines's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

BeOne Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeOne Medicines Ltd (STU:49B) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

BEIGF:USA ONC:USA 06160:Hong Kong 688235:China B1ME34:Brazil

Address

c/o BeOne Medicines I GmbH, Aeschengraben 27, 21st Floor, Basel, CHE, 4051

Website

https://www.beonemedicines.com

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

BeOne Medicines Headlines

No Headlines